Who are The MP/RP group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RAGWEED 12 AMB A 1-U, Escalation Therapies Group, Staloral TM, tree 12 SQ-Bet, sublingual allergen extract, AIT Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/the-mp-rp-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

The MP/RP group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The MP/RP group (The MP/RP group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunotherapy. Area: Immunology.

marketed Immunotherapy Immunology Small molecule Live · refreshed every 30 min

Target snapshot

The MP/RP group (The MP/RP group) — Beijing Tiantan Hospital. The MP/RP group is a type of immunotherapy that targets the immune system to treat various conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
The MP/RP group TARGET	The MP/RP group	Beijing Tiantan Hospital	marketed	Immunotherapy
RAGWEED 12 AMB A 1-U	RAGWEED 12 AMB A 1-U	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen extract immunotherapy	Ragweed pollen allergens (Amb a 1 and related epitopes)
Escalation Therapies Group	Escalation Therapies Group	The Cleveland Clinic	marketed	Immunotherapy
Staloral TM	Staloral TM	National Taiwan University Hospital	marketed	Allergen immunotherapy
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)
sublingual allergen extract	sublingual allergen extract	Medical University of Lodz	marketed	Sublingual immunotherapy (SLIT)
AIT Tablet	AIT Tablet	ALK-Abelló A/S	marketed	Allergen immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunotherapy class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
CytoVac A/S · 1 drug in this class
Hannover Medical School · 1 drug in this class
Pfizer · 1 drug in this class
The Cleveland Clinic · 1 drug in this class
Zarour, Hassane, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). The MP/RP group — Competitive Intelligence Brief. https://druglandscape.com/ci/the-mp-rp-group. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab